Peer-Reviewed Publications

• 74.    Dudley EK, Andraka-Christou B, Boland A, Pivovarova E, Atkins DN.  The Role of Social Relationships in Recovery Court Programs. Health & Justice (Impact factor 3.0; 1st Quartile in Law). 2025. Accepted and in press.
• 73.    Bailey A, Andraka-Christou B, Rouhani S, Clark MH, Atkins D, del Pozo B.  Beliefs of US chiefs of police about substance use disorder, fentanyl exposure, overdose response, and use of discretion: Results from a national survey. Health & Justice (Impact factor 3.0; 1st Quartile in Law). 2025; 13(1): 13. doi.org/10.1186/s40352-025-00318-8. Available at https://link.springer.com/article/10.1186/s40352-025-00318-8?utm_source=rct_congratemailt&utm_medium=email&utm_campaign=oa_20250305&utm_content=10.1186/s40352-025-00318-8  
• 72.    del Pozo B, Rouhani S, Bailey A, Clark MH, Martins K, Ahmed F, Atkins D, Andraka-Christou B. The effects of message framing on US police chiefs’ support for interventions for opioid use disorder: A randomized survey experiment. Health & Justice. (Impact factor 3.0; 1st Quartile in Law). 2025; 12: 50. doi.org/10.1186/s40352-024-00306-4. Avao;ab;e at https://healthandjusticejournal.biomedcentral.com/articles/10.1186/s40352-024-00306-4#citeas
• 71.    Pivovarova E, Taxman FS, Boland AK, Andraka-Christou B, de la Cruz BA, Semlson D, Lemon SC, Friedmann PD. Medication for Opioid Use Disorders (MOUD) Providers’ Experiences with Recovery Courts. Substance Use & Addiction Journal. 2025. In press. (Impact factor 3.5, available at https://journals.sagepub.com/home/saj; ranking unavailable; this journal is the official publication of The Association for Multidisciplinary Education and Research in Substance use & Addiction.)
• 70.    Andraka-Christou B, Viglione J, Ahmed F, del Pozo B, Atkins DN, Clark MH, Pivovarova E. Factors affecting problem-solving court team decisions about medications for opioid use disorder. Journal of Substance Use and Addiction Treatment (previously called The Journal of Substance Abuse Treatment). 2025;168:209525. (Impact factor 3.7; 1st Quartile in Substance Abuse). doi:10.1016/j.josat.2024.209525. Available at https://www.sciencedirect.com/science/article/pii/S2949875924002376?dgcid=author
• 69.    Kingsley J, Andraka-Christou B, Shah SK, Spicer P, Newman S, Ossorio PN. Navigating ethical and legal challenges in the HEALthy Brain and Child Development Study: Lessons learned from the ethics, law, policy working group. Developmental Cognitive Neuroscience. 2024;70:101460. (Impact factor 4.6; 1^st Quartile in Neurosciences).doi: 10.1016/j.dcn.2024.101460. Available at https://www.sciencedirect.com/science/article/pii/S187892932400121X
• 68.    del Pozo B, Rouhani S, Clark MH, Atkins D, Andraka-Christou B, Martins K. Understaffed and beleaguered: A national survey of US chiefs of police about the post-George Floyd era. Policing: An International Journal of Policy & Practice. 2024;47(5): 846-860. (Impact factor 1.3; 3^rd Quartile in Criminology & Penology). doi: 10.1108/PIJPSM-12-2023-0171. Available at https://www.emerald.com/insight/content/doi/10.1108/PIJPSM-12-2023-0171/full/html.
• 68.    Atkins DN, del Pozo B, Clark MH, Andraka-Christou B, O’Donnell D, Ray B. Disparities in the accuracy of reporting opioid overdoses to 9-1-1 by race and sex of overdose victim, Marion County, Indiana, 2011–2020. Health Justice. 2024;12: 25. doi: 10.1186/s40352-024-00279-4. (Impact factor 3.0; 1st Quartile in Law). Available at https://healthandjusticejournal.biomedcentral.com/articles/10.1186/s40352-024-00279-4  
• 67.    Golan, OK, Ahmed FZ, Andraka-Christou B, Totaram R^s, Asi Y, Atkins D. Impact of COVID-19 on Florida family dependency drug courts. Health Justice. 2024;12: 4. doi: 10.1186/s40352-024-00260-1. (Impact factor 3.0; 1st Quartile in Law). Available at https://healthandjusticejournal.biomedcentral.com/articles/10.1186/s40352-024-00260-1   
• 66.    Scheidell JD, Pitre M, Andraka-Christou B. Racial and ethnic inequities in substance use treatment among women with opioid use disorder. Am J Drug Alcohol Abuse. 2024;50(1):106-116. doi:10.1080/00952990.2023.2291748. (impact factor 2.7; 2^nd Quartile in Substance Abuse). Available at https://pubmed.ncbi.nlm.nih.gov/38295349/.
• 65.    Andraka-Christou B, Golan OK, Williams M, Buksbaum S, Gordon AJ, Stein BD. A Systematic Review of State Office-Based Buprenorphine Treatment Laws Effective During 2022: Counseling, Dosage, and Visit Frequency Requirements. Subst Use Addctn J. 2024;45(2):278-291. doi:10.1177/29767342231223721(impact factor 3.85; 2nd Quartile in Substance Abuse)
• 64.    Golan OK, Sheng F, Dick AW, Sorbero M, Whitaker DJ, Andraka-Christou B, Pigott T, Gordon AJ, Stein BD. Differences in Medicaid expansion effects on buprenorphine treatment utilization by county rurality and income: A pharmacy data claims analysis from 2009-2018. Drug Alcohol Depend Rep. 2023;9:100193. doi:10.1016/j.dadr.2023.100193 (impact factor 1.9; 3^rd Quartile in Substance Abuse). Available at https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10590758/.
• 63.    Agniel D, Cantor J, Golan OK, Yu H, Andraka-Christou B, Simon K, Stein BD, Taylor EA. How are state telehealth policies associated with services offered by substance use disorder treatment facilities? Evidence from 2019 to 2022. Drug Alcohol Depend. 2023;252:110959. doi:10.1016/j.drugalcdep.2023.110959 (impact factor 3.9; 1^st Quartile in Psychiatry). Available at: https://www.sciencedirect.com/science/article/pii/S0376871623011973.
• 62.    Andraka-Christou B, Atkins DD, Clark MH, Del Pozo B, Ray B. A National Survey of Problem-Solving Court Staff Perceptions of In-Person versus Virtual Hearings. J Am Acad Psychiatry Law. 2024;52(1):15-22. doi:10.29158/JAAPL.230075-23 (Impact factor 2.1; 1^st Quartile in Law). Available at: https://jaapl.org/content/early/2024/01/25/JAAPL.230075-23
• 61.    O’Neil MM, Andraka-Christou B, Kunkel T, Bryant K, Huynh P, Ray B. Treatment Court Staffs’ Perceptions in Support of the Use of Virtual Services in Court Post-Pandemic. Criminal Justice and Behavior. 2024; 51(2): 286-306. Doi: 10.1177/00938548231219807 (Impact factor 2.1; 1^st Quartile in Criminology & Penology). Available at https://journals.sagepub.com/doi/10.1177/00938548231219807.
• 60.    Andraka-Christou B, Williams M^s, Buksbaum S^s, Karkkainen J^s, Stein BD, Batchelder S, Peck K, Heil SS, Rawson R, Sigmon SC. US state laws relevant to incentives for health behavior: A qualitative analysis. Prev Med. 2023;176:107645. doi:10.1016/j.ypmed.2023.107645 (Impact factor 4.3; 1^st Quartile in Medicine, General & Internal). Available at https://www.sciencedirect.com/science/article/abs/pii/S0091743523002256?CMX_ID=&SIS_ID=&dgcid=STMJ_AUTH_SERV_PUBLISHED&utm_acid=91568011&utm_campaign=STMJ_AUTH_SERV_PUBLISHED&utm_in=DM394089&utm_medium=email&utm_source=AC_
• 59.    Andraka-Christou B, Atkins DN, Shields MC, Golan OK, Totaram R^s, Cortelyou K, Lambie GW, Mazurenko O. Key person-centered care domains for residential substance use disorder treatment facilities: former clients’ perspectives.  Subst Abuse Treat Prev Policy. 2023;18(1):45. (impact factor 3.0; 2^nd Quartile in Substance Abuse). Available at https://pubmed.ncbi.nlm.nih.gov/37461114/.
• 58.    Andraka-Christou B, McAvoy E, Gordon AJ, Ohama M, Brach M^s, Taylor EA, Vaiana M, Saloner B, Stein BD. Urine drug testing when prescribing opioid analgesics for chronic pain: A content analysis of U.S. state laws in 2022.  Pain Medicine. 2023;24(12): 1306-1317. doi: 10.1093/pm/pnad103. (Impact factor 2.9; 1^st Quartile in Medicine, General & Internal). Available at https://pubmed.ncbi.nlm.nih.gov/37551941/.
• 57.    Andraka-Christou B, Asi YM, Totaram R^s, Matusow H. Problem-Solving Court Staff Preferences for Educational Videos about Medications for Opioid Use Disorder. Subst Use Misuse. 2023. doi: 10.1080/10826084.2023.2236201 (impact factor 1.8; 3rd Quartile in Psychology). Available at https://www.tandfonline.com/doi/full/10.1080/10826084.2023.2236201.
• 56.    Saloner B, Andraka-Christou B, Stein BD, Gordon AJ. Will the End of the X-Waiver Expand Access to Buprenorphine Treatment? Achieving the Full Potential of the 2023 Consolidated Appropriations Act. Subst Abuse. 2023;44(3):108-111. doi: 10.1177/08897077231186212. (impact factor 2.8; 2nd Quartile in Substance Abuse). Available at https://pubmed.ncbi.nlm.nih.gov/37675897/.
• 55.    Andraka-Christou B, Simon K, Bradford WD, Nguyen T. Buprenorphine treatment for opioid use disorder: Comparison of insurance restrictions, 2017-2021. Health Aff (Millwood). 2023;42(5): 658–664. doi:10.1377/hlthaff.2022.01513 (Impact Factor 8.6; 1st Quartile in Health Policy & Services). Available at: https://www.healthaffairs.org/doi/abs/10.1377/hlthaff.2022.01513.
• 54.    Andraka-Christou B, Evans MD, Tranen B, Mendoza NS. Legal limitations associated with microdosing buprenorphine. Subst Use Misuse. 2023;1-4. doi:10.1080/10826084.2023.2196688 (impact factor 2.17; 3rd Quartile in Psychology). 
• 53.    Stein BD, Saloner BK, Golan OK, Andraka-Christou B, Andrews CM, Dick AW, Davis CS, Sheng F, Gordon AJ. Association of Selected State Policies and Requirements for Buprenorphine Treatment With Per Capita Months of Treatment. JAMA Health Forum. 2023;4(5):e231102. doi:10.1001/jamahealthforum.2023.1102 (impact factor 9.6; 1st Quartile in Health Policy & Services.)
• 52.    Andraka-Christou B, Golan O, Totaram R^s, Ohama M, Saloner B, Gordon AJ, Stein BD. Prior authorization restrictions on medications for opioid use disorder: trends in state laws from 2005 to 2019. Annals of Medicine. 2023; 55(1):514-520. doi:10.1080/07853890.2023.2171107.  (impact factor 4.9; 1^st Quartile in Medicine, General & Internal). Available at https://pubmed.ncbi.nlm.nih.gov/36724766/
• 51.    Andraka-Christou B, Golan OK, Totaram R^s, Shields M, Cortelyou K, Atkins D, Lambie G, Mazurenko O. Operationalizing person-centered care in residential substance use disorder treatment. Journal of Addictive Diseases. 2023; 42(4): 384–399. doi: 10.1080/10550887.2023.2247810. (impact factor 1.6; 3^rd Quartile in Substance Abuse). Available at https://pubmed.ncbi.nlm.nih.gov/37602811/
• 50.    del Pozo B, Atkins D, Andraka-Christou B, Wightman R, Clark MH, Huynh P, Ray B. Buprenorphine involvement in opioid overdose deaths: A retrospective analysis of postmortem toxicology in Marion County, Indiana, 2015-2021. Drug & Alcohol Dependence Reports. 2022;6; 100131 (impact factor 1.9; 3^rd Quartile in Substance Abuse). Available at https://www.sciencedirect.com/science/article/pii/S277272462300001X?via%3Dihub
• 49.    Bartholomew T, Andraka-Christou B, Totaram R^s, Harris S, Doblecki-Lewis S, Ostrer L, Serota DP, Forrest DW, Chueng T, Suarez E, Tookes HE. We want everything in a “one-stop shop”: Acceptability and feasibility of PReP and buprenorphine implementation with mobile syringe services for Black people who inject drugs. Harm Reduction Journal. 2022;19:133. doi:10.1186/s12954-022-00721-6 (impact factor 4; 1st Quartile in Substance Abuse). Available at https://harmreductionjournal.biomedcentral.com/articles/10.1186/s12954-022-00721-6
• 48.    Nguyen T, Andraka-Christou B, Arnaudo C, Bradford WD, Simon K, Spetz J. Analysis of US County Characteristics and Clinicians with Waivers to Prescribe Buprenorphine After Changes in Federal Education Requirements. JAMA Network Open. 2022;5(10):e2237912. doi:10.1001/jamanetworkopen.2022.37912 (impact factor 10.5; 1st Quartile in Medicine, General & Internal). Available at https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2797551
• 47.    Andraka-Christou B, McAvoy E^s, Ohama M, Smart R, Vaiana M, Taylor E, Stein BD. Systematic Identification and Categorization of Opioid Prescribing and Dispensing Policies in 16 States and Washington, DC. Pain Med. 2023;24(2):130-138. doi:10.1093/pm/pnac124 (Impact factor 2.9; 1^st Quartile in Medicine, General & Internal). Available at https://academic.oup.com/painmedicine/advance-article/doi/10.1093/pm/pnac124/6671855.
• 46.    Andraka-Christou B, Totaram R^s, Nguyen TD. Comprehensive analysis of discharge reasons from methadone outpatient treatment programs. Am J Addict. 2022;31(6):508-516. doi:10.1111/ajad.13326 (Impact factor 2.5; 2^nd Quartile in Substance Abuse). Available at: https://onlinelibrary.wiley.com/doi/10.1111/ajad.13326
• 45.    Andraka-Christou B, Page C, Schoebel V, Buche J, Haffajee RL. Perceptions of buprenorphine barriers and efficacy among nurse practitioners and physician assistants. Addict Sci Clin Pract. 2022;17(43). doi: 10.1186/s13722-022-00321-6 (Impact factor 3.7; 1^st Quartile in Substance Abuse). Available at: https://ascpjournal.biomedcentral.com/articles/10.1186/s13722-022-00321-6
• 44.    Ahmed F^s, Andraka-Christou B, Clark MH, Totaram R^s, Atkins DN, del Pozo. Barriers to medications for opioid use disorder in the court system: provider availability, provider “trustworthiness,” and cost. Health Justice. 2022;10(24). doi:10.1186/s40352-022-00188-4 (Impact factor 3.0; 1^st Quartile in Law). Available at: https://pubmed.ncbi.nlm.nih.gov/35895179/
• 43.    Nguyen TD, Chua KP, Andraka-Christou B, Bradford D, Simon K. Trends in Buprenorphine Coverage and Prior Authorization Requirements in US Commercial Formularies, 2017-2021. JAMA Health Forum. 2022;3(7):e221821. doi:10.1001/jamahealthforum.2022.1821 (Impact factor 9.6; 1st Quartile in Health Policy & Services.) Available at: https://jamanetwork.com/journals/jama-health-forum/fullarticle/2794135
• 42.    Andraka-Christou B, Saloner B, Gordon AJ, Totaram R^s, Randall-Kosich O^s, Golan M, Stein BD. Laws for expanding access to medications for opioid use disorder: a legal analysis of 16 states & Washington D.C. Am J Drug Alcohol Abuse. 2022;48(4):492-503. doi:10.1080/00952990.2022.2082301 (Impact Factor 2.7; 2^nd Quartile in Substance Abuse). Available at: https://pubmed.ncbi.nlm.nih.gov/35772010/
• 41.    Ray B, Kunkel T, Bryant K, Hedden B, Andraka-Christou B, O’Neil M, Huynh P. Client attitudes toward virtual treatment court. J Subst Abuse Treat. 2022;140:108833. doi:10.1016/j.jsat.2022.108833 (Impact factor 3.7; 1^st Quartile in Substance Abuse). Available at: https://pubmed.ncbi.nlm.nih.gov/35779292/
• 40.    Andraka-Christou B, Randall-Kosich O^s, Golan M, Totaram R^s, Saloner B, Gordon AJ, Stein BD. A national survey of state laws regarding medications for opioid use disorder in problem-solving courts. Health Justice. 2022;10(1):14. Published 2022 Mar 31. doi:10.1186/s40352-022-00178-6. (Impact factor 3.0; 1^st Quartile in Law). Available at: https://pubmed.ncbi.nlm.nih.gov/35357599/
• 39.    Andraka-Christou B, Nguyen T, Harris S, Atkins DN, Totaram R^s, Golan OK^s, Koval A, Madeira J. Harm reduction policy support among students at two US universities. Subst Use Misuse. 2022;57(8):1185-1195. doi:10.1080/10826084.2022.2069265 (impact factor 1.8; 3^rd Quartile in Psychology). Available at: https://pubmed.ncbi.nlm.nih.gov/35491710/
• 38.    Golan O^s, Totaram R^s, Perry E, Fortson K, Rivera-Atilano R^s, Entress R^s, Andraka-Christou B, Whitaker D, Pigott T. Systematic review and meta-analysis of changes in quality of life following initiation of buprenorphine for opioid use disorder. Drug Alcohol Depend. 2022;235:109445. doi:10.1016/j.drugalcdep.2022.109445 (impact factor 3.9; 1^st Quartile in Psychiatry). Available at: https://pubmed.ncbi.nlm.nih.gov/35430522/
• 37.    Harrison JM, Kerber R, Andraka-Christou B, Sorbero M, Stein BD. State Policies and Buprenorphine Prescribing by Nurse Practitioners and Physician Assistants. Med Care Res Rev. 2022;79(6):789-797. doi:10.1177/10775587221086489 (impact factor 2.4; 1st Quartile in Health Policy & Services). Available at: https://pubmed.ncbi.nlm.nih.gov/35435071/
• 36.    Andraka-Christou B, Gordon AJ, Spetz J, Totaram R^s, Golan M^s, Randall-Kosich O^s, Harrison JM, Calder S, Kertesz S, Stein BD. Beyond state scope of practice laws for advanced practitioners: Additional supervision requirements for buprenorphine prescribing. J Subst Abuse Treat. 2022;138:108715. doi:10.1016/j.jsat.2021.108715 (impact factor 3.7; 1^st Quartile in Substance Abuse). Available at:  https://pubmed.ncbi.nlm.nih.gov/35067400/
• 35.    Nguyen T, Andraka-Christou B, Bradford D, Simon K. Opting into the Public List of Data-Waivered Practitioners: Variations by Specialty, Treatment Capacity, and Practitioner Characteristics. J Addict Med. 2022;16(3):e197-e202. doi:10.1097/ADM.0000000000000911 (flagship journal of the American Society of Addiction Medicine; impact factor 4.2; 1^st Quartile in Substance Abuse). Available at: https://pubmed.ncbi.nlm.nih.gov/34669615/
• 34.    Andraka-Christou B, Totaram R^s, Randall-Kosich O^s. Stigmatization of medications for opioid use disorder in 12-step support groups and participant responses. Subst Abus. 2022;43(1):415-424. doi:10.1080/08897077.2021.1944957 (impact factor 2.8; 2^nd Quartile in Substance Abuse). Available at: https://pubmed.ncbi.nlm.nih.gov/34214400/
• 33.    Andraka-Christou B, Clark MH, Atkins DN, del Pozo B. Criminal problem-solving and civil dependency court policies regarding medications for opioid use disorder. Subst Abuse. 2021;43(1):425-432.  doi: 10.1080/08897077.2021.1944958 (impact factor 2.8; 2^nd Quartile in Substance Abuse). Available at: https://pubmed.ncbi.nlm.nih.gov/34236297/
• 32.    Andraka-Christou B. Addressing racial & ethnic disparities in utilization of medications for opioid use disorder. Health Aff (Millwood). 2021;40(6):920-927. doi:10.1377/hlthaff.2020.02261 (Impact Factor 7.03; 1^st Quartile in Health Policy & Services). Available at: https://pubmed.ncbi.nlm.nih.gov/34097509/
• 31.    Nguyen T, Cantor, J, Andraka-Christou B, Bradford W, Simon K. Where did the behavioral health workforce grow between 2011 and 2019? Evidence from census data. J Subst Abuse Treat. 2021;130:108482. doi: 10.1016/j.jsat.2021.108482. (impact factor 3.7; 1^st Quartile in Substance Abuse). Available at: https://pubmed.ncbi.nlm.nih.gov/34118714/
• 30.    Cantor J, Kravitz D, Sorbero M, Andraka-Christou B, Whaley C, Bouskill K, Stein B. Trends in visits to substance use disorder treatment facilities in 2019. J Subst Abuse Treat. 2021;130:108482. doi:10.1016/j.jsat.2021.108482 (impact factor 3.7; 1^st Quartile in Substance Abuse). Available at: https://pubmed.ncbi.nlm.nih.gov/34118714/
• 29.    Andraka-Christou B, Gordon A, Bouskill K, Smart R, Randall-Kosich O^s, Golan M^s, Totaram R^s, Stein B. Toward a typology of office-based buprenorphine treatment laws: Themes from a review of state laws. J Addict Med. 2022;16(2):192-207. doi:10.1097/ADM.0000000000000863 (flagship journal of the American Society of Addiction Medicine; impact factor 4.2; 1^st Quartile in Substance Abuse). Available at: https://pubmed.ncbi.nlm.nih.gov/34014209/
• 28.    Andraka-Christou B, Bouskill K, Haffajee R, Randall-Kosich O^s, Golan M^s, Totaram R^s, Gordon A, Stein B. Common themes in early state responses to substance use disorder treatment during COVID-19. Am J Drug Alcohol Abuse. 2021;47(4):486-496. doi:10.1080/00952990.2021.1903023 (Impact Factor 2.7; 2^nd in Substance Abuse). Available at: https://pubmed.ncbi.nlm.nih.gov/33909518/
• 27.    Nguyen T, Muench U, Andraka-Christou B, Simon K, Bradford WD, Spetz J. The Association between Scope of Practice Regulations and Nurse Practitioner Prescribing of Buprenorphine after the 2016 Opioid Bill. Med Care Res Rev. 2022;79(2):290-298. doi:10.1177/10775587211004311 (impact factor 2.4; 2^nd Quartile in Health Policy & Services). Available at: https://pubmed.ncbi.nlm.nih.gov/33792414/
• 26.    Saloner B, Andraka-Christou B, Gordon A, Stein B. It will end in tiers: A strategy to include “dabblers” in the buprenorphine workforce after the X-waiver. Subst Abuse. 2020;42(2):153-157. doi:10.1080/08897077.2021.1903659. (impact factor 3.85; 2^nd Quartile in Substance Abuse). Available at: https://pubmed.ncbi.nlm.nih.gov/33798034/
• 25.    Andraka-Christou B, Nguyen T, Harris S, Madeira J, Totaram R ^S, Randall-Kosich O ^S, Atkins D. A pilot study of U.S. college students’ 12-step orientation and the relationship with medications for opioid use disorder. J Am Coll Health. 2022;70(8):2383-2391. doi:10.1080/07448481.2020.1865376 (impact factor 1.6; 2^nd Quartile in Education, Educational Research). Available at: https://pubmed.ncbi.nlm.nih.gov/33577404/
• 24.    Andraka-Christou B, Randall-Kosich O ^S, Totaram R ^S. Designing an “ideal” substance use disorder treatment center: Perspectives of people who have utilized medications for opioid use disorder. Qual Health Res. 2021;31(3):512-522. doi:10.1177/1049732320971231 (impact factor 2.6; 2^nd Quartile in Social Sciences & Biomedical). Available at: https://pubmed.ncbi.nlm.nih.gov/33213261/
• 23.    Andraka-Christou B, Atkins D. Whose opinion matters about medications for opioid use disorder? A Cross-sectional survey of social norms among court staff. Subst Abus. 2021;42(4):735-750. doi:10.1080/08897077.2020.1846666 (impact factor 2.8; 2^nd Quartile in Substance Abuse). Available at: https://pubmed.ncbi.nlm.nih.gov/33284059/
• 22.    Andraka-Christou B, Atkins D. Beliefs about Medications for Opioid Use Disorder among Florida Criminal Problem-Solving Court & Dependency Court Staff. Am J Drug Alcohol Abuse. 2020;46(6):749-760. doi:10.1080/00952990.2020.1807559 (Impact Factor 3.67; Quartile 2 in Substance Abuse). Available at: https://pubmed.ncbi.nlm.nih.gov/32969757/
• 21.    Haffajee R, Andraka-Christou B, Attermann J, Cupito A, Buche J, Beck A. A mixed-method comparison of physician-reported beliefs about and barriers to treatment with medications for opioid use disorder. Subst Abuse Treat Prev Policy. 2020;15(1):69. doi:10.1186/s13011-020-00312-3 (impact factor 3.12; H index 40; 3rd Quartile in Substance Abuse). Available at: https://pubmed.ncbi.nlm.nih.gov/32928272/
• 20.    Mazurenko O, Andraka-Christou, B, Bair M, Kara A, Harle C. Clinical perspectives on hospitals’ role in the opioid epidemic. BMC Health Serv Res. 2020;20(1):521. doi:10.1186/s12913-020-05390-4 (impact factor 3.3; 3^rd Quartile in Health Care Sciences & Services). Available at: https://pubmed.ncbi.nlm.nih.gov/32513158/
• 19.    Andraka-Christou B, Atkins D, Madeira J, Silverman R. Receipt of Training about Medication for Opioid Use Disorder from Pharmaceutical Manufacturers: A Preliminary Study of Florida Criminal Problem-Solving and Dependency Court Staff. Drug Alcohol Rev. 2020;39(5):583-587. doi:10.1111/dar.13090 (impact factor 3.3; 3^rd Quartile in Health Care Sciences & Services). Available at: https://pubmed.ncbi.nlm.nih.gov/32394525/
• 18.    Andraka-Christou B, Nguyen T, Harris S, Madeira J, Randall-Kosich O^s, Totaram R^s, Atkins D, Ford J. College students’ perceived knowledge of and perceived helpfulness of treatments for opioid use disorder at two American universities. Am J Drug Alcohol Abuse. 2020;46(5):589-603. doi:10.1080/00952990.2020.1757686 (Impact Factor 3.67; Quartile 2 in Substance Abuse). Available at: https://pubmed.ncbi.nlm.nih.gov/32543922/
• 17.    Andraka-Christou B, Nguyen T, Bradford D, Simon K. Assessing the Impact of Drug Courts on Provider-Directed Marketing Efforts by Manufactures of Medications for the Treatment of Opioid Use Disorder. J Subst Abuse Treat. 2020;110:49-58. doi:10.1016/j.jsat.2019.12.004 (impact factor 4.0; 2^nd Quartile in Substance Abuse). Available at: https://pubmed.ncbi.nlm.nih.gov/31952628/
• 16.    Nguyen T, Andraka-Christou B, Simon K, Bradford D. Comparison of rural versus urban direct-to-physician commercial promotion of medications for treating opioid use disorder. JAMA Netw Open. 2019;2(12):e1916520. doi:10.1001/jamanetworkopen.2019.16520 (impact factor 8.5; 1st Quartile in Medicine – General & Internal). Available at: https://pubmed.ncbi.nlm.nih.gov/31790568/
• 15.    Dilulio J, Militello L, Andraka-Christou B, Cook R, Hurley R, Downs S, Anders S, Mamlin B, Danielson E^s, Harle C. Factors that influence changes to existing chronic pain management plans. J Am Board Fam Med. 2020;33(1):42-50. doi:10.3122/jabfm.2020.01.190284 (impact factor 3.01; 2^nd Quartile in Medicine – General & Internal). Available at: https://pubmed.ncbi.nlm.nih.gov/31907245/
• 14.    Staton M, Andraka-Christou B, Watson D. Isomorphic pressures on jail diversion: From serious mental illness to opioid use disorder. The Prison Journal. 2021;101(2):187-209. doi:10.1177/0032885521991092 (impact factor 1.63; 4^th Quartile in Criminology). Available at: https://journals.sagepub.com/doi/abs/10.1177/0032885521991092
• 13.    Danielson E, Mazurenko O, Andraka-Christou B, Dilulio J, Downs S, Hurley R, Harle C. An analysis of primary care clinician communication about risk, benefits, and goals, related to opioid therapy. MDM Policy Pract. 2019;4(2):2381468319892572. doi:10.1177/2381468319892572 (impact factor 3.6; 2^nd Quartile in Health Policy & Services). Available at: https://pubmed.ncbi.nlm.nih.gov/31853506/
• 12.    Randall-Kosich O^s, Andraka-Christou B, Totaram R^s, Alamo J^s, Nadig M^s. Comparing Reasons for Starting and Stopping Methadone, Buprenorphine, and Naltrexone Treatment among a Sample of White Individuals with Opioid Use Disorder. J Addict Med. 2020;14(4):e44-e52. doi:10.1097/ADM.0000000000000584 (flagship journal of the American Society of Addiction Medicine; impact factor 3.93; 2^nd Quartile in Substance Abuse). Available at: https://pubmed.ncbi.nlm.nih.gov/31651562/  
• 11.    Andraka-Christou B, Gabriel M, Madeira J, Silverman R. Court personnel attitudes towards medications for opioid use disorder: a state-wide survey. J Subst Abuse Treat. 2019;104:72-82. doi:10.1016/j.jsat.2019.06.011 (impact factor 4.0; 2^nd Quartile in Substance Abuse). Available at: https://pubmed.ncbi.nlm.nih.gov/31370988/
• 10.    Nguyen T, Andraka-Christou B, Bradford W, Kosali S. Provider-Directed Marketing May Increase Prescribing of Medications for Opioid Use Disorder. J Subst Abuse Treat. 2019;104:104-115. doi:10.1016/j.jsat.2019.06.014 (impact factor 4.0; 2^nd Quartile in Substance Abuse). Available at: https://pubmed.ncbi.nlm.nih.gov/31370974/
• 9.      Andraka-Christou B, Alex B^s, Madeira J. College student preferences regarding educational videos and substance use disorder content, format, and style. Subst Use Misuse. 2019;54(8):1400-1407. doi:10.1080/10826084.2019.1581816 (impact factor 2.17; 3^rd Quartile in Psychology). Available at: https://pubmed.ncbi.nlm.nih.gov/30860935/
• 8.      Mazurenko O, Andraka-Christou B, Bair M, Kara A, Harle C. A. Balancing patient-centered and safe pain care for non-surgical inpatients: clinical and managerial perspectives. Jt Comm J Qual Patient Saf. 2019;45(4):241-248. doi:10.1016/j.jcjq.2018.11.004 (impact factor 2.3; H-index 79; 2^nd Quartile in Health Care Sciences & Services). Available at: https://pubmed.ncbi.nlm.nih.gov/30591269/
• 7.      Andraka-Christou B, Rager J, Brown-Podgorski B, M, Silverman, R, Watson, D. An integrative systematic review of the medical literature on pain clinic definitions and comparison with existing state laws and regulations. Subst Abuse Treat Prev Policy. 2018;13(1):17. doi:10.1186/s13011-018-0153-6 (impact factor 3.3; 3rd Quartile in Substance Abuse). Available at: https://pubmed.ncbi.nlm.nih.gov/29789018/
• 6.      Andraka-Christou B, Capone M^S. Qualitative Study Comparing Physician-Reported Barriers to Buprenorphine & Extended-Release Naltrexone Prescribing in U.S. Office-Based Practices. Int J Drug Policy. 2018;54:9-17. doi:10.1016/j.drugpo.2017.11.021 (impact factor 5.3; 1st Quartile in Substance Abuse). Available at: https://pubmed.ncbi.nlm.nih.gov/29324253/
• 5.      Arnaudo C, Andraka-Christou B, Algood K. Psychiatric Co-Morbidities in Pregnant Women with Opioid Use Disorders: Prevalence, Impact, and Implications for Treatment. Curr Addict Rep. 2017;4(1):1-13. doi:10.1007/s40429-017-0132-4 (impact factor 4.3; 1^st Quartile in Substance Abuse). Available at: https://pubmed.ncbi.nlm.nih.gov/28357191/
• 4.      Andraka-Christou B. A Pressing Need for Pharmacotherapy Development to Treat Drug Addiction: An Editorial from a Legal Perspective. Int Rev Neurobiol. 2016;126:15-38. doi:10.1016/bs.irn.2016.02.003 (impact factor 4.3; Quartile 2 in Neurosciences). Available at: https://pubmed.ncbi.nlm.nih.gov/27055610/
• 3.      Madeira JL, Andraka-Christou B. Paper Trails, Trailing Behind: Improving Informed Consent to IVF through Multimedia Applications. J Law Biosci. 2016;3(1):2-38. Published 2016 Jan 18. doi:10.1093/jlb/lsv054 (impact factor 3.4; H-index 18; 1^st Quartile in Law). Available at: https://pubmed.ncbi.nlm.nih.gov/27774231/
•  2.     Andraka-Christou B. America Needs the TREAT Act: Expanding Access to Effective     Medication for Treating Addiction. Health Matrix Clevel. 2016;26:309-362. PMID: 27263255 (peer-reviewed law journal; impact factor 0.24; quartile not assigned; impact factor and quartile are from SCIMAGO, because unavailable from Journal Citation Reports). Available at: https://pubmed.ncbi.nlm.nih.gov/27263255/
• Andraka-Christou B. Public Policy Lessons from the Orphan Drug Act: Applications for Health Policy Advocates. J Entrepreneurship Public Policy.2015; 4(3): 278-297. doi: 10.1108/JEPP-12-2013-0052 (impact factor 1.9; 2^nd Quartile in Economics). Available at: https://www.emerald.com/insight/content/doi/10.1108/JEPP-12-2013-0052/full/html

Other Publications

• 24.    Nguyen ND, Andraka-Christou B, Buchwalder K, Bradford WD, Simon K. To Battle The Fentanyl Overdose Epidemic, Modernize Methadone Treatment. Health Affairs Forefront. August 20, 2024. doi: 10.1377/forefront.20240815.54389. Available at: https://www.healthaffairs.org/content/forefront/battle-fentanyl-overdose-epidemic-modernize-methadone-treatment
• 23.    Scheidell JD, Andraka-Christou B. Response to Reed and Socias letter. The American Journal of Drug and Alcohol Abuse. 2024. doi: 10.1080/00952990.2024.2365861. Available at: https://www.tandfonline.com/doi/full/10.1080/00952990.2024.2365861
• 22.    Totaram R ^S, Ahmed F ^S, Andraka-Christou B, Asi Y, Atkins D. Family Dependency Drug Court Service Modifications During COVID-19. 2022 Poster Abstracts. Conference abstract published in Journal of Addiction Medicine 16(5):p e284-e347, 9/10 2022. doi: 10.1097/ADM.0000000000001068.
• 21.    Totaram R ^S, Ahmed F ^S, Andraka-Christou B, Atkins D, Asi Y. Service Modifications During COVID-19 and its Impact on Problem-Solving Courts. International Association of Forensic Mental Health Services Newsletter. 2022;7(1):7. Available at: http://iafmhs.org/resources/Documents/Newsletter/IAFMHS%20Newsletter%202022%207(1)%20Winter%20.pdf
• 20.    Andraka-Christou B, Atkins D, Clark MH, del Pozo B. Problematic Policies Regarding Medications for Opioid Use Disorder among Florida Courts. 2021 Poster Abstracts. Conference abstract published in Journal of Addiction Medicine 15(5):p E1-E58, September/October 2021. doi: 10.1097/ADM.0000000000000902
• 19.    Andraka-Christou B, Clark MH, Atkins D. Training Impacts Some Court Staff Beliefs about Medications for Opioid Use Disorder. 2021 Poster Abstracts. Conference abstract published in Journal of Addiction Medicine 15(5):p E1-E58, September/October 2021. doi: 10.1097/ADM.0000000000000902
• 18.    Andraka-Christou B, Atkins D, Asi Y. Mentoring Female & Minoritized Doctoral Students: Results and Lessons Learned. Pre-Academia Mentoring Pod, University of Central Florida: Orlando, Florida. 2021. Available at: https://ccie.ucf.edu/wp-content/uploads/sites/12/2021/11/Pre-AcademiaMentoringPod.pdf
• 17.    Andraka-Christou B, Koval A, Belanger K ^S, Randall-Kosich O ^S, Totaram R ^S, Atkins D, Mazurenko O. Operationalization of Person-Centered Care: A Survey of Staff in South Florida Health Facilities. Person-Centered Care in Behavioral Health Working Group, University of Central Florida: Orlando, Florida. 2021. Available at: https://ccie.ucf.edu/wp-content/uploads/sites/12/2021/02/Final-PCC-Staff-Report.pdf
• 16.    Andraka Christou B., Belanger K ^S, Koval A ^S, Totaram R ^S., Randall-Kosich O ^S, Atkins D , Mazurenko O. Operationalization of Person-Centered Care: A Survey of Clients in South Florida Health Facilities. Person-Centered Care in Behavioral Health Working Group, University of Central Florida: Orlando, Florida. 2021. Available at: https://ccie.ucf.edu/wp-content/uploads/sites/12/2021/02/Final-PCC-Client-Report.pdf
• 15.    Andraka-Christou, B. Eight Dimensions of Person-Centered Care Critical to Improving Substance Use Disorder Treatment. Person-Centered Care in Behavioral Health Working Group, Academy Health: Washington, D.C. 2020. Available at: https://academyhealth.org/sites/default/files/researchtoimprovepccforsud_october2020.pdf
• 14.    Andraka‐Christou B, Gordon A, Bouskill K, Smart R, Randall-Kosich O ^S, Golan M ^S, Totaram R ^S, Stein BD. Toward a typology of office-based buprenorphine treatment laws: themes from a review of state laws. Conference abstract published in Addict Sci Clin Pract. 2020; 15(2): A107. (impact factor 4; 2^nd Quartile in Substance Abuse). Available at: https://ascpjournal.biomedcentral.com/articles/10.1186/s13722-020-00208-4
• 13.    Randall-Kosich O ^S, Andraka‐Christou B. Reasons for Starting and Stopping Methadone, Buprenorphine, and Naltrexone Treatment. 2020 ASAM Virtual Poster Abstracts. Journal of Addiction Medicine 14(6):p e382-e424, November/December 2020. doi: 10.1097/ADM.0000000000000742
• 12.    Randall-Kosich O ^S, Andraka‐Christou B, Totaram R ^S, Cortelyou-Ward K, Atkins D, Koval A. Operationalizing person-centered care in behavioral health treatment: how can treatment centers implement respect for patient values, preferences, and expressed needs? Conference abstract published in Addict Sci Clin Pract. 2020; 15(2): A100. (impact factor 4; 2^nd Quartile in Substance Abuse). Available at: https://ascpjournal.biomedcentral.com/articles/10.1186/s13722-020-00208-4
• 11.    Watson D, Andraka‐Christou B, Clark T, Wiegandt J. Introduction to the special issue on innovative interventions and approaches to expand medication assisted treatment: Seizing research opportunities made available by the opioid STR program. J Subst Abuse Treat. 2020; 108: 1-3. doi: 10.1016/j.jsat.2019.10.004. (impact factor 4.0; 2^nd Quartile in Substance Abuse).  Available at: https://pubmed.ncbi.nlm.nih.gov/31668689/
• 10.    Page C, Andraka-Christou B, Buche J, Foney D, Beck A. Nurse Practitioner and Physician Assistant Provision of MAT for Opioid Use Disorder. 2019 Poster Abstracts. Conference abstract published in Journal of Addiction Medicine 13(3):p E1-E42, May/June 2019. doi: 10.1097/ADM.0000000000000548
• 9.      Andraka-Christou B, Gabriel M, Madeira J, Silverman R. Indiana Court Employees’ Attitudes Towards Medication-assisted Treatments for OUD. 2019 Poster Abstracts. Conference abstract published in Journal of Addiction Medicine 13(3):p E1-E42, May/June 2019. doi: 10.1097/ADM.0000000000000548
• 8.      Danielson EC, Mazurenko O, Andraka‐Christou B, DiIulio J, Downs SM, Hurley RW, Harle CA. How do primary care clinicians and patients discuss risks, benefits, and goals in chronic opioid therapy? Peer-reviewed abstract in J Pain. 2018; 19(3): S73‐74. (impact factor 7; 1^st Quartile in Neurosciences). Available at: https://www.jpain.org/article/S1526-5900(17)30982-3/fulltext
• 7.      Andraka-Christou, B. Individuals Suffering from Substance Use Disorder Need Treatment, Not Prisons. Ohio State University, Moritz School of Law, Drug Enforcement & Policy Center. Expert commentary. 2018. Available at: https://moritzlaw.osu.edu/depc/wp-content/uploads/sites/115/2018/10/Barbara-Andraka-Christou.pdf
• 6.      Haffajee R, Andraka-Christou B, Foney D, Beck A, Page C, Buche J. Nurse Practitioner and Physician Assistant Provision of Medication-Assisted Treatment for Opioid Use Disorder: A Survey of Knowledge, Engagement, and Perceptions. University of Michigan Behavioral Health Workforce Research Center. October 2018. Available at: http://www.behavioralhealthworkforce.org/wp-content/uploads/2019/01/Y3-FA3-P2-NP-PA-MAT-Full-Report.pdf
• 5.      Atterman J, Dormond M, Schreiber J, Haffajee R, Andraka-Christou B, Singer P, Haworth S, Foney D, Pozuelos S. Behavioral Workforce Implementation Challenges Related to Medication-Assisted Treatment. University of Michigan Behavioral Health Workforce Research Center. 2018. Available at: http://www.behavioralhealthworkforce.org/wp-content/uploads/2018/04/Y2FA3P2_MAT-Full-Report.pdf.
• 4.      Andraka-Christou, B. Improving Drug Courts through Medication-Assisted Treatment for Addiction. Va J Soc Pol Law. 2016; 23(2): 179-229. (law journal). Available at: https://heinonline.org/HOL/LandingPage?handle=hein.journals/vajsplw23&div=11&id=&page=
• Andraka-Christou, B. What is Treatment for Opiate Addiction in Problem- Solving Courts? A Study of 20 Indiana Drug and Veterans Courts. Stanford J CRCL. 2017; 13(2): 189-254. Available at: https://law.stanford.edu/publications/what-is-treatment-for-opioid-addiction-in-problem-solving-courts-a-study-of-20-indiana-drug-and-veterans-courts/
• Andraka-Christou B. A Qualitative Study of Substance Abuse Treatment Practices and Policies in Indiana Drug and Veterans Courts. 2016 Poster Abstracts. Conference abstract published in Journal of Addiction Medicine 10(3):p E1-E20, May/June 2016. doi: 10.1097/ADM.0000000000000224
• Andraka-Christou, B. Bringing SUD Treatment into Mainstream Medicine. Guest Column. Indiana State Medical Association Reports. 2016; 12: 6. *